Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OKL-1111
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Broadview Ventures
Deal Size : $5.2 million
Deal Type : Financing
Alveron Secures €5M Seed Extension Financing for Intracranial Hemorrhage Therapy
Details : The financing aims to advance the development of its innovative drug, OKL-1111, for the treatment of intracranial haemorrhage.
Product Name : OKL-1111
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 12, 2024
Lead Product(s) : OKL-1111
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Broadview Ventures
Deal Size : $5.2 million
Deal Type : Financing
Reset All
